Back to All Combinations
KRAS G12V
Intermediate PrognosisGenes Involved
KRAS
Treatment Implications
Second most common KRAS. No specific inhibitor yet.
Recommended Treatments
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
Treatments to Avoid
Anti-EGFR
Study References
Meta-analyses
Key Statistics
8.00%
Prevalence in CRC
No
Targetable
Clinical Notes
May have slightly worse prognosis than G12D.
Information
Category: RAS Pathway
Evidence Level: Level 2A
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.